16 / 17
Allied Journal of Medical Research
|
Volume 2
Page 39
Note:
allied
academies
CANCER THERAPY AND ONCOLOGY
NEUROLOGY AND BRAIN DISORDERS
&
International Conference on
International Conference on
J u n e 2 1 - 2 2 , 2 0 1 8 | O s a k a , J a p a n
Joint Event on
ALTERNATIVE SPLICING OF
EXTENDED SYNAPTOTAGMIN-2 AS A
PROGNOSTIC BIOMARKER IN RENAL
CELL CARCINOMA
Dan Huang
1
, FY Hu
1
and
Nelson Tang
1,2
1
Department of Chemical Pathology, Faculty of Medicine - The Chinese University
of Hong Kong, Hong Kong, China
2
Li Ka Shing Institute of Health Sciences, Faculty of Medicine - The Chinese Univer-
sity of Hong Kong, Hong Kong, China
T
he protein of gene ESYT2 Extended synaptotagmin-2 has been
demonstrated to be interacted with the Fibroblast Groth Factor
Receptor and activated FGF receptor. It plays an important role in growth
factor signaling. However, the expression and function of the transcript
variants of this gene is unclear in cancer. In this study, we observed a
significant isoform switch of ESYT2 based on the RNA-seq data of
the renal cell carcinoma (KIRC) samples downloaded from the TCGA
database. Although the expression level of gene ESYT2 is higher in KIRC
tumor samples, the expression ratio of the long ESYT2 isoform (ESYT2-L)
which includes a cassette exon between exons 13 and 14 to the short
isoform (ESYT2-S) is higher in kidney normal samples. The Kaplan-Meier
survival curves showed that samples with higher expression ratio of
ESYT2-L are associated with better survival (p=2.04e-06). Multivariate
Cox proportional hazards regression revealed that the expression
ratio of the ESYT2-L could be as an independent prognostic factor for
patients with CRC (hazard ratio, 0.037; 95% confidence interval, 0.01-
0.125; P=1.24e-07). In addition, the Gene set enrichment analysis (GSEA)
revealed that genes correlated with the expression ratio of ESYT2-L is
enriched in hallmark of the EMT and invasiveness signature from cancer
cell. In conclusion, our findings show that the alternative splicing of
ESYT2 could be a potential prognostic biomarker in KIRC and samples
with lower expression ratio of the ESYT2-L isoform may be more likely to
have the potential to become metastatic.
Dan Huang is a PhD candidate from The Chi-
nese University of Hong Kong. She has been in-
volved in the design, application, and evaluation
of bioinformatics pipelines for transcriptome
studies based on high throughput sequencing
data. She mainly focus on the alternative splic-
ing events that may be associated with cancer
by studying large genetic and genomic datasets
downloaded from The Cancer Genome Atlas
(TCGA) database.
dan.huang0909@gmail.comBIOGRAPHY
Dan Huang et al., Allied J Med Res 2018, Volume 2